Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.

Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Aley PK, Bhikha S, Hermanus T, Horne E, Jose A, Kgagudi P, Lambe T, Masenya M, Masilela M, Mkhize N, Moultrie A, Mukendi CK, Moyo-Gwete T, Nana AJ, Nzimande A, Patel F, Rhead S, Taoushanis C, Thombrayil A, van Eck S, Voysey M, Villafana TL, Vekemans J, Gilbert SC, Pollard AJ, Moore PL, Kwatra G, Wits VIDA COVID team

Open source

DOI
10.1016/s2352-3018(21)00157-0
Published
2021 Sep
Container
The lancet. HIV
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3018-21-00157-0,
  title = {Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.},
  author = {Madhi SA and Koen AL and Izu A and Fairlie L and Cutland CL and Baillie V and Padayachee SD and Dheda K and Barnabas SL and Bhorat QE and Briner C and Aley PK and Bhikha S and Hermanus T and Horne E and Jose A and Kgagudi P and Lambe T and Masenya M and Masilela M and Mkhize N and Moultrie A and Mukendi CK and Moyo-Gwete T and Nana AJ and Nzimande A and Patel F and Rhead S and Taoushanis C and Thombrayil A and van Eck S and Voysey M and Villafana TL and Vekemans J and Gilbert SC and Pollard AJ and Moore PL and Kwatra G and Wits VIDA COVID team},
  year = {2021},
  journal = {The lancet. HIV},
  doi = {10.1016/s2352-3018(21)00157-0},
  url = {https://doi.org/10.1016/s2352-3018(21)00157-0}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
AU  - Madhi SA
AU  - Koen AL
AU  - Izu A
AU  - Fairlie L
AU  - Cutland CL
AU  - Baillie V
AU  - Padayachee SD
AU  - Dheda K
AU  - Barnabas SL
AU  - Bhorat QE
AU  - Briner C
AU  - Aley PK
AU  - Bhikha S
AU  - Hermanus T
AU  - Horne E
AU  - Jose A
AU  - Kgagudi P
AU  - Lambe T
AU  - Masenya M
AU  - Masilela M
AU  - Mkhize N
AU  - Moultrie A
AU  - Mukendi CK
AU  - Moyo-Gwete T
AU  - Nana AJ
AU  - Nzimande A
AU  - Patel F
AU  - Rhead S
AU  - Taoushanis C
AU  - Thombrayil A
AU  - van Eck S
AU  - Voysey M
AU  - Villafana TL
AU  - Vekemans J
AU  - Gilbert SC
AU  - Pollard AJ
AU  - Moore PL
AU  - Kwatra G
AU  - Wits VIDA COVID team
PY  - 2021
JO  - The lancet. HIV
DO  - 10.1016/s2352-3018(21)00157-0
UR  - https://doi.org/10.1016/s2352-3018(21)00157-0
ER  -

APA

SA, M., AL, K., A, I., L, F., CL, C., V, B., SD, P., K, D., SL, B., QE, B., C, B., PK, A., S, B., T, H., E, H., A, J., P, K., T, L., M, M., M, M., N, M., A, M., CK, M., T, M., AJ, N., A, N., F, P., S, R., C, T., A, T., S, V. E., M, V., TL, V., J, V., SC, G., AJ, P., PL, M., G, K., & team, W. V. C. (2021). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.. The lancet. HIV. https://doi.org/10.1016/s2352-3018(21)00157-0

Source records